Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hydroxyurea induced acute elevations in liver function tests.

Mike J Hallam1, Jill M Kolesar

  • 1University of Wisconsin, School of Pharmacy, Madison, WI 53792, USA.

Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|March 14, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Precision oncology's translation gap-Can molecular tumor boards bridge it?

PLoS medicine·2026
Same author

A case report of acute carcinoid heart failure during lutetium-177 dotatate-triapine treatment for well-differentiated neuroendocrine tumors.

Frontiers in oncology·2026
Same author

A Phase 1 Dose Escalation of Lapatinib and Paclitaxel in Recurrent Ovarian Cancer.

Cancers·2026
Same author

Inhibition of fatty acid synthase enhances therapeutic efficacy and delays acquired resistance to BRAF-targeted therapy in colorectal cancer.

Neoplasia (New York, N.Y.)·2026
Same author

Assessing the Value of Sequential Next-Generation Sequencing and Multiple Molecular Tumor Board Reviews for Patients With Solid-Tumor Malignancies.

JCO precision oncology·2026
Same author

M1 Macrophage-Engineered Vesicles Have Anti-Cancer Activity in Ovarian Cancer.

Cancer nanotechnology·2026
Same journal

Impact of community pharmacy-based telephone follow-up on treatment completion in cancer patients receiving adjuvant chemotherapy: A retrospective observational study.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026
Same journal

Polypharmacy and clinical outcomes in geriatric patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor pathway inhibitors.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026
Same journal

Therapeutic potential of aspirin in metastatic brain disease: A narrative review bridging evidence from systemic cancers to brain metastasis.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026
Same journal

Incidence of neutropenia with intrathecal pemetrexed for leptomeningeal disease associated with solid tumors - A retrospective analysis.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026
Same journal

Bridging the pain gaps: Opioid access for cancer pain in rural Nepal and the untapped role of pharmacists.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026
Same journal

Low fixed dose rasburicase for tumour lysis syndrome prophylaxis and treatment is feasible and efficacious in the management of haematologic malignancies.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026
See all related articles

Hydroxyurea (HU) can cause rare side effects like fever, nausea, and liver enzyme elevations in patients with polycythemia vera (PV) or essential thrombocythemia (ET). Prompt symptom resolution after stopping HU highlights its potential toxicity.

Area of Science:

  • Hematology
  • Pharmacology
  • Internal Medicine

Background:

  • Hydroxyurea (HU) is a standard treatment for myeloproliferative neoplasms like polycythemia vera (PV) and essential thrombocythemia (ET).
  • It functions as a ribonucleotide reductase inhibitor, impacting DNA synthesis.

Observation:

  • An 82-year-old male with PV developed anorexia, nausea, vomiting, fever, fatigue, dizziness, and shaking chills 8 days after starting HU.
  • Symptoms resolved within 2 days of HU discontinuation.
  • Upon restarting HU, the patient experienced nausea and anorexia, accompanied by elevated liver function tests that resolved after stopping the medication.

Findings:

  • Hydroxyurea can induce a rare but significant adverse event profile.
  • Observed side effects include gastrointestinal distress, constitutional symptoms (fever, chills, fatigue), and hepatotoxicity.

Related Experiment Videos

  • These adverse effects appear to be reversible upon medication cessation.

    • Implications:

    • Clinicians should counsel patients initiating Hydroxyurea on potential rare side effects, including fever, chills, nausea, and liver enzyme abnormalities.
    • Vigilant monitoring for these adverse events is crucial during HU therapy.
    • Early recognition and discontinuation of HU can lead to prompt symptom resolution and prevent further complications.